Benralizumab, an anti–interleukin-5-receptor antibody, was evaluated in a 24-week study involving 12 patients with chronic spontaneous urticaria. The disease was assessed on the basis of urticaria activity scores. After three monthly injections and 2 months without benralizumab, 5 patients had a complete response and 2 had a partial response.
소스: October 1, 2020
N Engl J Med 2020; 383:1389-1391
DOI: 10.1056/NEJMc2016395